Elekta High Resolution, Quick Attach/Detach Multi-leaf Collimator Will Facilitate More “On Demand” Stereotactic Treatments in the Clinic

Elekta High Resolution, Quick Attach/Detach Multi-leaf Collimator Will
Facilitate More “On Demand” Stereotactic Treatments in the Clinic

Elekta receives FDA 510(k) clearance for Apex dynamic multi-leaf
collimator (DMLC)

With its 2.5 mm leaf width across the largest field size (12 x 14 cm)
and a convenient attach and detach mechanism, Elekta's Apex™ DMLC is the
right beam shaping solution for clinics that encounter cases in which a
stereotactic approach is needed.
“Apex combines the right technical specifications with the ability to be
rapidly attached and removed, making it the ideal solution for routine
treatment of stereotactic cases throughout the day,” says Kevin Brown,
Global Vice President, Scientific Research. “This DMLC also features low
transmission, small penumbra and sharp dose gradients - all specifically
to facilitate static and dynamic stereotactic treatments of
head-and-neck targets.”
The Apex DMLC's 112 leaves feature a dual focus design, which reduces
the penumbra, thereby creating a steep dose fall off, and increasing the
linearity across the whole field. To minimize transmission between leaf
junctions, Apex was designed with a central axis tongue and groove leaf
tip. The DMLC's 2.5 mm leaf width across the entire 12 x 14 cm field
size also improves conformance of the smallest head and neck targets by
eliminating the stepping effect between leaf ends, which occurs with
wider MLC leaves. In addition, full, independent interdigitation enables
treatment of island fields or multiple targets in the same fraction.
The integrated attach and release mechanism of Apex creates a seamless
interface to the integrated Elekta MLC radiation head. The new design
allows the DMLC to be securely mounted and calibrated quickly and easily
using the automated calibration procedure that is provided with the
product.
Additional features:

  · Compatible with Elekta treatment systems equipped with MLCi™ or
MLCi2™
  · Supports static, IMRT and dynamic techniques from 6MV to 18MV
  · Supports ERGO++™ and Monaco® R3.0
  · Validated with MOSAIQ® R2.0

*Approval of indications may vary between different
countries. Additional regulatory clearances may be required in some
markets.

For further information, please contact:
Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, email:
stina.thorman@elekta.com (stina.thorman@elekta.com)
Time zone: CET: Central European Time
Michelle Lee Joiner, Director, Global Public Relations and Brand
Management, Elekta
Tel: +1 770-670-2447, email:
michelle.joiner@elekta.com (michelle.joiner@elekta.com)
Time zone: ET: Eastern Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial
Instruments Trading Act. The information was published at 15.00 CET on
November 8, 2011.
About Elekta
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The company
develops sophisticated, state-of-the-art tools and treatment planning
systems for radiation therapy, radiosurgery and brachytherapy, as well
as workflow enhancing software systems across the spectrum of cancer
care. Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that offer confidence to
both healthcare providers and patients, Elekta aims to improve, prolong
and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over
6,000 hospitals worldwide. Elekta employs around 3,300 employees
globally. The corporate headquarters is located in Stockholm, Sweden,
and the company is listed on the Nordic Exchange under the ticker EKTAb.
Website: www.elekta.com (http://www.elekta.com).